Regeneron (REGN) Misses Q1 EPS by 15c, Offers FY Guidance
Regeneron (NASDAQ: REGN) reported Q1 EPS of $2.92, $0.15 worse than the analyst estimate of $3.07. Revenue for the quarter came in at $1.32 billion versus the consensus estimate of $1.3 billion.
2017 Financial Guidance(3)
The Company's updated full year 2017 financial guidance consists of the following components:
EYLEA U.S. net product sales | Single digit percentage growth over 2016 (reaffirmed) | |||
Sanofi reimbursement of Regeneron commercialization-related expenses | $385 million - $425 million (previously $400 million - $450 million) | |||
Non-GAAP unreimbursed R&D(2)(4) | $950 million - $1.025 billion (reaffirmed) | |||
Non-GAAP SG&A(2)(4) | $1.140 billion - $1.200 billion (previously $1.175 billion - $1.250 billion) | |||
Effective tax rate | 32% - 38% (reaffirmed) | |||
Capital expenditures | $300 million - $350 million (previously $375 million - $450 million) |
For earnings history and earnings-related data on Regeneron (REGN) click here.